Auvray M, et al. - Researchers assessed the outcomes with vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKIs) after first-line nivolumab-ipilimumab failure in patients with metastatic renal cell carcinomas (mRCCs). A total of 33 patients who received subsequent TKI after nivolumab-ipilimumab failure, as part of Checkmate 214 study were reviewed in 13 institutions, with 22 months (19–NR) of median follow-up from the start of subsequent TKI. Partial responses, stable diseases, and progressive diseases were seen in 12 (36%), 13 (39%), and 5 (15%) patients, respectively. From start of TKI, 8 months [5–13] was the median progression-free survival (PFS). Median PFS of 8 months [5–16] and 7 months (5–NA) was reported with first-generation (sunitinib/pazopanib) and second-generation TKI (axitinib/cabozantinib), respectively. In this first report addressing the efficacy of TKI after first-line nivolumab-ipilimumab failure, a sustained benefit of TKI was reflected by median PFS.